Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8.

PMID:
30635226
2.

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.

Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, Black C, Brunskill NJ, Carrero JJ, Feldman HI, Fox CS, Inker LA, Ishani A, Ito S, Jassal S, Konta T, Polkinghorne K, Romundstad S, Solbu MD, Stempniewicz N, Stengel B, Tonelli M, Umesawa M, Waikar SS, Wen CP, Wetzels JFM, Woodward M, Grams ME, Kovesdy CP, Levey AS, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127. doi: 10.1016/S2213-8587(18)30313-9. Epub 2019 Jan 8.

PMID:
30635225
3.

Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.

Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.

Lancet Diabetes Endocrinol. 2016 Apr;4(4):309-17. doi: 10.1016/S2213-8587(15)00469-6. Epub 2016 Jan 14.

PMID:
26774608
4.

The Validity of Drug Effects on Proteinuria, Albuminuria, Serum Creatinine, and Estimated GFR as Surrogate End Points for ESKD: A Systematic Review.

Palmer SC, Ruospo M, Teixeira-Pinto A, Craig JC, Macaskill P, Strippoli GFM.

Am J Kidney Dis. 2018 Dec;72(6):779-789. doi: 10.1053/j.ajkd.2018.06.011. Epub 2018 Aug 24.

5.

Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data.

Matsushita K, Ballew SH, Coresh J, Arima H, Ärnlöv J, Cirillo M, Ebert N, Hiramoto JS, Kimm H, Shlipak MG, Visseren FLJ, Gansevoort RT, Kovesdy CP, Shalev V, Woodward M, Kronenberg F; Chronic Kidney Disease Prognosis Consortium.

Lancet Diabetes Endocrinol. 2017 Sep;5(9):718-728. doi: 10.1016/S2213-8587(17)30183-3. Epub 2017 Jul 14.

6.

Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis.

Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).

Am J Kidney Dis. 2014 Jul;64(1):74-85. doi: 10.1053/j.ajkd.2014.02.020. Epub 2014 Apr 29.

7.

The kidney and cardiovascular outcome trials.

Bloomgarden Z.

J Diabetes. 2018 Feb;10(2):88-89. doi: 10.1111/1753-0407.12616.

PMID:
29031006
8.

Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.

Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP, Katafuchi R, Appel GB, Maes BD, Li PK, Praga M, Del Vecchio L, Andrulli S, Manno C, Gutierrez E, Mercer A, Carroll KJ, Schmid CH, Levey AS.

Am J Kidney Dis. 2016 Sep;68(3):392-401. doi: 10.1053/j.ajkd.2016.02.042. Epub 2016 Mar 29.

PMID:
27032886
9.

GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials.

Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, Coresh J, Greene T, Levey AS.

Am J Kidney Dis. 2014 Dec;64(6):848-59. doi: 10.1053/j.ajkd.2014.08.017. Epub 2014 Oct 16.

PMID:
25441438
10.

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.

Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C.

Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621. doi: 10.1016/S2213-8587(17)30182-1. Epub 2017 Jun 27.

PMID:
28666775
11.

Glucose targets for preventing diabetic kidney disease and its progression.

Ruospo M, Saglimbene VM, Palmer SC, De Cosmo S, Pacilli A, Lamacchia O, Cignarelli M, Fioretto P, Vecchio M, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2017 Jun 8;6:CD010137. doi: 10.1002/14651858.CD010137.pub2. Review.

PMID:
28594069
12.

Interventions for chronic kidney disease in people with sickle cell disease.

Roy NB, Fortin PM, Bull KR, Doree C, Trivella M, Hopewell S, Estcourt LJ.

Cochrane Database Syst Rev. 2017 Jul 3;7:CD012380. doi: 10.1002/14651858.CD012380.pub2. Review.

13.

GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials.

Lambers Heerspink HJ, Tighiouart H, Sang Y, Ballew S, Mondal H, Matsushita K, Coresh J, Levey AS, Inker LA.

Am J Kidney Dis. 2014 Dec;64(6):860-6. doi: 10.1053/j.ajkd.2014.08.018. Epub 2014 Oct 16.

PMID:
25441439
14.

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B.

Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.

15.
16.

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT.

Lancet. 2010 Jun 12;375(9731):2073-81. doi: 10.1016/S0140-6736(10)60674-5. Epub 2010 May 17.

17.

Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.

Badve SV, Palmer SC, Hawley CM, Pascoe EM, Strippoli GF, Johnson DW.

Nephrol Dial Transplant. 2016 Sep;31(9):1425-36. doi: 10.1093/ndt/gfv269. Epub 2015 Jul 11. Review.

PMID:
26163881
18.

Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis.

Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, Iseki K, Jassal SK, Kimm H, Kronenberg F, Oien CM, Levey AS, Levin A, Woodward M, Hemmelgarn BR; Chronic Kidney Disease Prognosis Consortium.

BMJ. 2013 Jan 29;346:f324. doi: 10.1136/bmj.f324. Review.

19.

Biotic Supplements for Renal Patients: A Systematic Review and Meta-Analysis.

Pisano A, D'Arrigo G, Coppolino G, Bolignano D.

Nutrients. 2018 Sep 4;10(9). pii: E1224. doi: 10.3390/nu10091224.

20.

Albuminuria, Proteinuria, and Renal Disease Progression in Children with CKD.

Fuhrman DY, Schneider MF, Dell KM, Blydt-Hansen TD, Mak R, Saland JM, Furth SL, Warady BA, Moxey-Mims MM, Schwartz GJ.

Clin J Am Soc Nephrol. 2017 Jun 7;12(6):912-920. doi: 10.2215/CJN.11971116. Epub 2017 May 25.

Supplemental Content

Support Center